Last reviewed · How we verify
Td alone
Td is a toxoid-based vaccine that provides immunization against tetanus and diphtheria by stimulating antibody production against inactivated bacterial toxins.
Td is a toxoid-based vaccine that provides immunization against tetanus and diphtheria by stimulating antibody production against inactivated bacterial toxins. Used for Tetanus prophylaxis and immunization, Diphtheria prophylaxis and immunization.
At a glance
| Generic name | Td alone |
|---|---|
| Sponsor | Korea University Guro Hospital |
| Drug class | Toxoid vaccine |
| Target | Tetanus toxin and diphtheria toxin |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Td vaccine contains inactivated toxins (toxoids) from Clostridium tetani and Corynebacterium diphtheriae. These toxoids are unable to cause disease but retain immunogenicity, triggering the adaptive immune system to produce protective antibodies and cellular immunity against tetanus and diphtheria toxins. This provides long-term protection against these potentially fatal bacterial infections.
Approved indications
- Tetanus prophylaxis and immunization
- Diphtheria prophylaxis and immunization
Common side effects
- Injection site pain, redness, or swelling
- Fever
- Myalgia
- Headache
Key clinical trials
- A Study on the Novel Oncolytic Virus Combined With PD-1 Inhibitor in the Treatment of Recurrent High-grade Glioma (PHASE1)
- Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS (PHASE3)
- ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients (PHASE1)
- PREDICTT Clinical Trial: Prospective Evaluation Of Pressure-Enabled Delivery And Alterations In CT-Based Tumor-To-Normal Liver Ratio And Tumor Dose Using The Trinav Infusion System (NA)
- Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae (PHASE2)
- Neoadjuvant Therapy With Ensartinib Combined With Chemotherapy for ALK-positive Non - Small Cell Lung Cancer (NSCLC) (PHASE1, PHASE2)
- Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma (PHASE1)
- Single-Center, Double-Blind, Randomized, Placebo-Controlled Study on Efficacy and Safety of rTMS (With Precise Localization) in Relieving Motor Symptoms of TD (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Td alone CI brief — competitive landscape report
- Td alone updates RSS · CI watch RSS
- Korea University Guro Hospital portfolio CI